| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $20.6M | -0.8% | +1.4% |
| SG&A Expense | $9.6M | -9.6% | +60.1% |
| Operating Income | -$30.3M | +3.8% | -14.8% |
| Net Income | -$29.6M | +2.8% | -21.9% |
| EPS (Basic) | -$0.14 | +0.0% | -27.3% |
| EPS (Diluted) | -$0.14 | +0.0% | -27.3% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $16.3M | -6.6% | -24.0% |
| Short-term Investments | $108.1M | -16.2% | -45.4% |
| Current Assets | $128.2M | -15.1% | -43.4% |
| Total Assets | $140.9M | -13.9% | -41.0% |
| Current Liabilities | $16.8M | +23.0% | +31.0% |
| Long-term Debt |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$76.0M | — | — |
| Capital Expenditures | $20K | — | — |
| Investing Cash Flow | $75.1M | — | — |
| Financing Cash Flow | $2.2M | — | — |
| Free Cash Flow | -$76.0M | — | — |
| $29.8M |
| +0.4% |
| +12.2% |
| Total Liabilities | $46.5M | +7.5% | +17.9% |
| Stockholders' Equity | $94.4M | -21.7% | -52.7% |